QUESTCOR PHARMACEUTICALS 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2010
QUESTCOR PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: (510) 400-0700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On September 8, 2010, Questcor Pharmaceuticals, Inc. (the Company) issued a press release regarding its supplemental new drug application for H.P. Acthar® Gel (repository corticotropin injection). The press release also provided certain interim financial information for the Companys third fiscal quarter.
The Company has scheduled a conference call for Thursday, September 9, 2010 at 9:00 a.m. Eastern Time, 6:00 a.m. Pacific Time, to discuss these recent developments, as set forth below and in the press release.
A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein.
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.